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During the screening of human lymphoblastoid cells as suitable hosts for retrovirus transmission studies, the Epstein–Barr
virus (EBV)-negative, B-lymphoblastoid cell line DG-75 was found to be chronically infected with a heretofore unrecognized
retrovirus. Two DG-75 sublines obtained from different sources (designated UW and KAR) were found to produce constitu-
tively particles identified as retroviral by electron microscopy and reverse transcriptase activity. The ultrastructure, mor-
phogenesis, and density in sucrose of the particles were typical of C-type retroviruses. Immunoblot analysis of the
DG-75(UW) retrovirus proteins showed antigenic similarity to Moloney murine leukemia virus. A third DG-75 subline in early
passage, designated HAD, was free of retrovirus. The DG-75(UW) retrovirus was infectious and produced progeny virions
that could be passaged to uninfected cells. We have thus demonstrated that DG-75 cells, which have been used extensively
in studies of the biological effects of EBV-encoded genes and their promoters, may be chronically infected with a murine
retrovirus and that an early passage subline is retrovirus free and available for such studies. © 1998 Academic Press
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INTRODUCTION
The human B-lymphoblastoid cell line, DG-75, was orig-
inally isolated from the pleural effusion of a child with a
primary abdominal Burkitt-like lymphoma (Ben-Bassat et
al., 1977) and unlike many B-cell lines was shown to be
negative for Epstein–Barr virus (EBV). DG-75 cells are
readily transfectable and have been widely used to express
EBV genes involved in EBV latency and transformation
(Welinder et al., 1987; Cuomo et al., 1990; Fåhraeus et al.,
1993, 1994; Silins and Sculley 1995; Floettmann et al., 1996;
Sjo¨blom et al., 1998). During screening by electron micros-
copy and reverse transcriptase (RT) assays of EBV-negative
B-cell lines as potential hosts for a novel retrovirus, JHK
virus (Grossberg et al., 1997), it was found that the DG-
75(UW) subline received by our laboratory was productively
infected with a retrovirus.
RESULTS
Electron microscopy of ultracentrifuged virions from
the DG-75(UW) cells revealed enveloped particles of
136 6 10-nm diameter, with 7-nm-long peplomers (Fig.
1A). Ultrathin sections of DG-75(UW) cells showed bud-
ding virus particles with characteristic C-type retroviral
morphogenesis (Frank, 1987) during egress from the cell
(Figs. 1B and 1C). A somewhat earlier passage of a
DG-75 subline, designated KAR, also contained retrovi-
rus-like particles (data not shown). Nearly 100% of the
cells of the DG-75(UW) and (KAR) sublines examined by
ultrathin section electron microscopy expressed virus
particles, whereas no virus was observed in the early
passage DG-75 cells obtained from Dr. Ben-Bassat, Ha-
dassah Medical Center, designated the HAD subline.
The UW and KAR particles had reverse transcriptase
(RT) activity as determined by the highly sensitive, PCR-
based, product-enhanced RT (PERT) assay. The demon-
stration of RT activity required concentrations of .0.05%
Triton X-100 for disruption of virus particles. The cation
preference for the RT activity of the DG-75(UW) virus was
tested over a range of 0–5 mM Mn21 and 0–13 mM
Mg21, showing an optimum activity at 1.4 mM Mn21.
Cell culture supernatant and 100,000 g ultracentri-
fuged pellets of the three DG-75 sublines were tested for
RT activity by PERT assay. The supernatants and pellets
from the KAR and UW sublines were strongly RT positive,
and the HAD subline was RT negative (Fig. 2), confirming
the electron microscopic observations. RT activity was
demonstrated to be associated with pelleted virus parti-
cles, whereas no RT activity was detected in culture
supernatant fluids centrifuged at 100,000 g for 1 h at 4°C
(Fig. 2).
Figure 3 shows the distribution of reverse transcrip-
tase activity in fractions from a sucrose gradient in which
DG-75(UW) virus was ultracentrifuged to equilibrium. A
distinct RT peak was observed at 35% sucrose, corre-
sponding to a density of 1.15 g/ml, which is within the
range reported for retroviruses (Murphy and Kingsbury,
1990). The small shoulder at 47% sucrose contained
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nucleocapsids stripped of their envelope (Gerwin et al.,
1970; Kotler et al., 1977; unpublished data).
To establish the possible antigenic relationship of the
DG-75(UW) retrovirus to known retroviruses, a virus
preparation was used as antigen in immunoblots and
reacted with a panel of anti-retroviral antisera (Fig. 4).
Sera specific to five different C-type retroviruses reacted
with a 30-kDa protein in the DG-75(UW) viral preparation.
DG-75 viral proteins did not react with antisera to retro-
viruses of B-type mouse mammary tumor virus (MMTV)
or D-type Mason-Pfizer monkey virus (MPMV) and squir-
rel monkey retrovirus (SMRV), as shown in Fig. 4. Of the
anti-C-type sera used, antibody to Moloney murine leu-
kemia virus (M-MLV) was the most reactive against the
DG-75(UW) viral proteins, of 110, 30, and ,15 kDa. This
antiserum also revealed a 30-kDa protein in viral pellets
prepared from the KAR subline, whereas no immunore-
active bands were observed with either culture superna-
tant fluids or cell lysates of the HAD subline (data not
shown).
Because immunoblot analysis indicated that the
DG-75 retrovirus was antigenically related to M-MLV, it
was necessary to determine whether the DG-75 sublines
were contaminated by murine cells. Flow cytometry was
performed using antisera specific for human CD-19 and
CD-20 and showed that the HAD, UW, and KAR sublines
were indeed human cells of B lineage, whereas all three
sublines were negative with an anti-mouse IgM antibody
(data not shown).
The potential infectivity of the DG-75 retrovirus was
determined by transmission of the virus to the DG-
75(HAD) subline, which was shown to be retrovirus-free
by electron microscopy, PERT assay, and immunoblot.
After the DG-75(UW) virus was adsorbed to DG-75(HAD)
cells, particle-associated RT activity in culture superna-
tant and ultrastructural changes in the cells were fol-
lowed periodically to monitor virus production. RT activity
was subsequently demonstrated in 100,000 g viral pel-
lets but not in mock-infected control cell cultures (Fig. 5),
and electron microscopic examination of the infected
HAD cells showed them to be actively producing C-type
particles. Progeny virus from the infected HAD sublines
were also shown to be transmissible to fresh retrovirus-
free HAD cell cultures (Figure 5).
DISCUSSION
The constitutive production of a C-type retrovirus by a
human B-lymphoblastoid cell line is very unusual. The
D-type SMRV has been reported to infect the human
B-lymphoblastoid cell line BJAB as well as marmoset
B-cell sublines B95–8K and B95–8N (Popovicˇ et al., 1982)
and further could undergo recombination with EBV in the
B95–8K cell line (Sun et al., 1995). SMRV was also found
FIG. 1. Demonstration of a C-type retrovirus in DG-75(UW) cells. (A) Negatively stained particle of DG-75(UW) retrovirus. (B) and (C) Budding virus
in ultrathin sections of DG-75(UW) cells.
FIG. 2. Particle-associated reverse transcriptase activity from DG-75
sublines. The PCR product-enhaned reverse transcriptase (PERT) as-
say was performed on the cell culture supernatant, the ultracentrifuged
viral pellets, and the resultant supernatant fluids (clarified SN). The
bound radioactivity was detected by autoradiography and counted
using a radioanalytical imaging system (AMBIS, San Diego, CA).
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to contaminate the human B-lymphoblastoid cell line
HBL (Oda et al., 1988).
The original source of infection of the DG-75 cells by
this murine retrovirus is unknown. We have demon-
strated that an early passage of DG-75 cells obtained
from Hannah Ben-Bassat, and designated here as the
HAD subline, is free of retrovirus by electron microscopy
and by the highly sensitive, PCR-based, product-
enhanced assay for reverse transcriptase. The practice
of growing human tumor cells in immunodeficient mice
has resulted in infection of the human cells by xenotropic
murine viruses (Levy, 1973; Todaro et al., 1973). The
investigators who have carried these sublines in their
laboratories have indicated that there was no attempt to
introduce by transfection a murine leukemia virus infec-
tious clone or to passage the cells in nude mice, a
circumstance that was reported to account for retroviral
contamination of the human B-lymphoblastoid cell line
Ramos (Kotler et al., 1977).
DG-75 cells have been used to study EBV gene ex-
pression, particularly at the level of transcription
(Fåhraeus et al., 1990) as well as to identify the activities
of genes involved in EBV immortalization and oncogenic
transformation (Finke et al., 1992; Sjo¨blom 1998). It is
conceivable that the DG-75 cells used in some of those
experiments could have been producing the retrovirus
described herein. We have shown that the HAD subline
is free of this retrovirus and available for such experi-
ments. A comparison of the nucleotide sequence of the
DG-75 retrovirus with sequences of other retroviruses,
particularly M-MLV, should provide insight into not only
the mutations that may have occurred to adapt its growth
in human B-lymphoblastoid cells but also possible re-
combinations that may occur with endogenous human
retrovirus sequences (Pandey et al., 1991; Chakrabarti et
al., 1994). The sequencing of the DG-75 retrovirus ge-
nome is now underway. In view of the many current
efforts to design better retroviral gene-therapy vectors,
especially those based on murine leukemia virus, a char-




Human B-lymphoblastoid, EBV-negative DG-75 cell
sublines were received from Bill Sugden, University of
Wisconsin-Madison (UW); George Klein, Karolinska Insti-
tute, Stockholm (KAR); and Hannah Ben-Bassat, Hadas-
sah Medical Center, Jerusalem (HAD). The cells were
maintained in RPMI medium 1640 supplemented with
10% fetal bovine serum, glutamine, and antibiotics.
Virus isolation and purification
Cell culture supernatant fluids were centrifuged at
15,000 g for 15 min followed by filtration through a 0.2-mm
filter. Virus particles were removed from the cell culture
supernatant fluids by ultracentrifugation at 100,000 g for
1 h at 4°C through a 20% sucrose cushion in TEN (10 mM
Tris-HCl, pH 7.3; 1 mM EDTA; 50 mM NaCl) buffer. The
resulting viral pellet was suspended in TEN buffer for
electron microscopy or TKDG (50 mM Tris-HCl, pH 8.3;
50 mM KCl; 5 mM DTT; 0.5 mM PMSF; 10 U/ml RNase
inhibitor; 10% glycerol) buffer for RT assays.
FIG. 3. Distribution of reverse transcriptase activity in a sucrose
gradient of cell-culture supernatant fluid from DG-75(UW) cells. Frac-
tions were collected from the bottom of the gradient and tested for RT
activity by PERT assay.
FIG. 4. Immunoblot of DG-75(UW) virus antigen reacted with various
retroviral antisera. Virus antigen was prepared from a sucrose-gradi-
ent-purified, PERT-positive fraction. The following primary goat antisera
were used: mouse mammary tumor virus (MMTV), Moloney murine
leukemia virus (M-MLV), baboon endogenous virus (BEV), feline leuke-
mia virus (FeLV), FeLV variant (RD114), inter-species retrovirus (GIV),
Mason-Pfizer monkey virus (MPMV), and squirrel monkey retrovirus
(SMRV). After incubation with the secondary antiserum, anti-goat-HRP
(Sigma, St. Louis, MO), the blot was developed with the ECL system
(Amersham, Arlington Heights, IL).
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For virus purification, cell-culture supernatant fluid
was centrifuged at 1000 g for 15 min followed by suc-
cessive filtration through 0.45- and 0.2-mm filters. Virus
from the cell culture supernatant was precipitated over-
night at 4°C with PEG-8000 and NaCl to a final concen-
tration of 9.5% and 100 mM, respectively (Poiesz et al.,
1980). The resulting precipitate was separated at 10,000
g for 30 min at 4°C and resuspended in TEN buffer. The
virus suspension was overlaid upon a step-gradient of 20
and 40% sucrose in TEN buffer, centrifuged at 100,000 g
for 1 h at 4°C, and the interface between 20 and 40%
sucrose was removed and diluted 1:2 in TEN buffer.
Diluted interface material was overlaid on a 20–60%
continuous sucrose gradient and centrifuged to equilib-
rium at 70,000 g for 16 h at 4°C. Fractions were collected
from the bottom of the gradient and examined for RT
activity. Virus was pelleted from the RT-positive fractions
by first diluting in TEN buffer, 1:4, followed by ultracen-
trifugation at 100,000 g for 1 h at 4°C. The virus pellet
was resuspended in TKDG buffer for RT assays or in gel
loading buffer for immunoblot analysis.
Electron microscopy
DG-75 cells and virus pellets were examined by elec-
tron microscopy as described previously (Grossberg et
al., 1997). Briefly, 5 3 106 cells were fixed in 2% glutar-
aldehyde in 0.1 M cacodylate buffer, postfixed with 1%
OsO4 in veronal-acetate buffer, pH 7.0, for 2 h, dehy-
drated in ethanol, and infiltrated and embedded in Poly-
bed (Polysciences, Warrington, PA). After polymerization,
the cells were thin sectioned and poststained with uranyl
acetate and lead citrate.
Negative staining was performed on virus pellets ob-
tained by ultracentrifugation of 0.2-mm filtered, cell-cul-
ture supernatant through a 20% sucrose cushion. The
resulting viral pellet was suspended in TEN buffer, ad-
sorbed to Formvar-coated copper grids, and stained with
2% sodium phosphotungstate, pH 7.0; samples were ob-
served with a EM400 HTG Philips microscope at direct
magnifications of 28,000–60,000.
Reverse transcriptase assay
The PCR-based, product-enhanced reverse tran-
scriptase (PERT) assay described by Pyra et al., (1994)
was used to test for RT activity. Briefly, this technique
employed an internal primer annealed to a heteropoly-
mer template, MS-2 bacteriophage RNA (Bio-Rad, Her-
cules, CA). The primed RNA, if reverse-transcribed,
would yield a cDNA, which would be amplified by PCR,
separated on an 2.5% agarose gel, and transferred to
a nylon membrane. An MS-2 internal primer was end-
labeled with 32P as a probe and hybridized to the blot
under stringent conditions; bound radioactivity was
detected by autoradiography and counted with a ra-
dioanalytical imaging system (AMBIS, San Diego, CA)
(Grossberg et al., 1997).
Immunoblot
Virus antigen was prepared from a sucrose-gradient-
purified, PERT-positive fraction as described above. the
viral antigen was denatured at 100°C in gel loading
buffer and subjected to 12% SDS–PAGE after which the
antigen was transferred to a nitrocellulose membrane,
which was blocked with 10% milk in TBST (20 mM Tris-
HCl, pH 7.5; 137 mM NaCl; 0.05% Tween 20) buffer.
Primary antisera diluted in 5% milk-TBST were added to
individual lanes with a multiscreen apparatus (Bio-Rad,
Hercules, CA) and incubated for 1 h at room tempera-
ture. The blot was washed three times with TBST buffer,
and the secondary antiserum, anti-goat-HRP (Sigma,
St. Louis, MO) was applied for 1 h at room temperature.
The blot was washed and developed with the ECL sys-
tem (Amersham, Arlington Heights, IL). Primary goat
antisera against the following retroviral preparations
were obtained from the NCI/BCB Repository (Quality
Biotech, Camden, NJ) and included: mouse mammary
tumor virus (MMTV) (04–0252), Moloney murine leuke-
mia virus (M-MLV) (04–0176), baboon endogenous virus
(BEV) (04–0076), feline leukemia virus (FeLV) (04–0016),
FeLV variant (RD114) (04–0027), interspecies retrovirus
(GIV) (04–0308), Mason-Pfizer monkey virus (MPMV) (04–
0307), and squirrel monkey retrovirus (SMRV) (04–0310).
FIG. 5. Infection of DG-75(HAD) cells by DG-75(UW) retrovirus. Pel-
lets, obtained after ultracentrifugation of cell culture supernatants
through 20% sucrose, were examined for PERT activity from the follow-
ing DG-75 cultures: Lane 1, UW positive control; lanes 2 and 4, HAD cell
cultures 10 and 21 days, respectively, after infection with the DG-
75(UW) virus; lanes 3 and 5, control HAD cell cultures 10 and 21 days,
respectively, after mock-infection; lane 6, HAD cell culture 14 days after
infection with supernatant fulid taken from the first HAD culture that
had been infected with the UW virus 300 days before.
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Virus transmission
Supernatant fluids from the DG-75(UW) or experimen-
tally infected DG-75(HAD) cell cultures were centrifuged
at 15,000 g for 15 min at 4°C followed by filtration through
a 0.2-mm filter. Crude virus-containing supernatant from
DG-75(UW) was added to 2 3 106 DG-75(HAD) cells/ml
in the presence of Polybrene (2 mg/ml) for 2 h at 36°C,
then an equal volume of culture medium was added, and
the cultures were incubated at 36°C for 18 h, when the
medium was changed. The culture was passaged
weekly, and the supernatant was monitored periodically
for particle-associated RT activity using the PERT assay.
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